December 21, 2018
Life Science Institute President Seiichi Kiso Life Science Institute said on December 20 that it has initiated an exploratory clinical trial of the multi-lineage differentiating stress enduring (Muse) cell product CL2020 in patients with epidermolysis bullosa. This is the third...read more